繊維芽細胞活性化タンパク質阻害剤のパイプライン・インサイト2019

【英語タイトル】Fibroblast Activation Protein (FAP or Seprase) Inhibitors -Pipeline Insights, 2019

DelveInsightが出版した調査資料(DIMR2016283)・商品コード:DIMR2016283
・発行会社(調査会社):DelveInsight
・発行日:2020年09月
・ページ数:約60
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD1,250 ⇒換算¥131,250見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD2,500 ⇒換算¥262,500見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートでは、世界における繊維芽細胞活性化タンパク質阻害剤のパイプライン動向について調査・分析し、以下の構成でお届けいたします。

・繊維芽細胞活性化タンパク質阻害剤の概要
・繊維芽細胞活性化タンパク質阻害剤のパイプライン概要
・企業別開発中の繊維芽細胞活性化タンパク質阻害剤
・後期治験段階の薬剤(Filed & Phase III):比較分析
・中期治験段階の薬剤(Phase II):比較分析
・初期治験段階の薬剤(Phase I & IND Filed):比較分析
・薬剤候補のプロファイル
・繊維芽細胞活性化タンパク質阻害剤の評価
  - 単剤治療薬別評価
  - 併用治療薬別評価
  - 投与経路別評価
  - 分子種類別評価
・開発が中止された薬剤リスト
・開発休止中の薬剤リスト
・繊維芽細胞活性化タンパク質阻害剤開発に取り組んでいる企業リスト
・図表一覧
【レポートの概要】

SUMMARY
DelveInsight’s, “Fibroblast Activation Protein (FAP or Seprase) Inhibitors-Pipeline Insights, 2019”, report provides in depth insights on the pipeline drugs and their development activities around the Fibroblast Activation Protein (FAP or Seprase) Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Fibroblast Activation Protein (FAP or Seprase) Inhibitors. DelveInsight’s Report also assesses the Fibroblast Activation Protein (FAP or Seprase) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.


Scope
• The report provides competitive pipeline landscape of Fibroblast Activation Protein (FAP or Seprase) Inhibitors
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Fibroblast Activation Protein (FAP or Seprase) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Fibroblast Activation Protein (FAP or Seprase) Inhibitors and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


【レポートの目次】

Table of Contents
• Fibroblast Activation Protein (FAP or Seprase) Inhibitors Overview
• Fibroblast Activation Protein (FAP or Seprase) Inhibitors Disease Associated
• Fibroblast Activation Protein (FAP or Seprase) Inhibitors Pipeline Therapeutics
• Fibroblast Activation Protein (FAP or Seprase) Inhibitors Therapeutics under Development by Companies
• Fibroblast Activation Protein (FAP or Seprase) Inhibitors Filed and Phase III Products
• Comparative Analysis
• Fibroblast Activation Protein (FAP or Seprase) Inhibitors Phase II Products
• Comparative Analysis
• Fibroblast Activation Protein (FAP or Seprase) Inhibitors Phase I and IND Filed Products
• Comparative Analysis
• Fibroblast Activation Protein (FAP or Seprase) Inhibitors Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• Fibroblast Activation Protein (FAP or Seprase) Inhibitors – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Fibroblast Activation Protein (FAP or Seprase) Inhibitors – Discontinued Products
• Fibroblast Activation Protein (FAP or Seprase) Inhibitors – Dormant Products
• Companies Involved in Therapeutics Development for Fibroblast Activation Protein (FAP or Seprase) Inhibitors
• Appendix
• Methodology
• Contact Us
• Disclaimer

List of Tables
• Number of Products under Development for Fibroblast Activation Protein (FAP or Seprase) Inhibitors by Therapy Area, 2019
• Number of Products under Development for Fibroblast Activation Protein (FAP or Seprase) Inhibitors, 2019
• Number of Products under Development by Companies
• Comparative Analysis by Filed and Phase III Products, 2019
• Comparative Analysis Phase II Products, 2019
• Comparative Analysis Phase I and IND Filed Products, 2019
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2019
• Drug Candidates Profiles
• Fibroblast Activation Protein (FAP or Seprase) Inhibitors Assessment by Monotherapy Products
• Fibroblast Activation Protein (FAP or Seprase) Inhibitors Assessment by Combination Products
• Fibroblast Activation Protein (FAP or Seprase) Inhibitors Assessment by Route of Administration
• Fibroblast Activation Protein (FAP or Seprase) Inhibitors Assessment by Stage and Route of Administration
• Fibroblast Activation Protein (FAP or Seprase) Inhibitors Assessment by Molecule Type
• Fibroblast Activation Protein (FAP or Seprase) Inhibitors Assessment by Stage and Molecule Type
• Fibroblast Activation Protein (FAP or Seprase) Inhibitors Therapeutics – Discontinued Products
• Fibroblast Activation Protein (FAP or Seprase) Inhibitors Therapeutics – Dormant Products
• Products under Development by Companies, 2019


List of Figures
• Number of Products under Development for Fibroblast Activation Protein (FAP or Seprase) Inhibitors by Therapy Area, 2019
• Number of Products under Development for Fibroblast Activation Protein (FAP or Seprase) Inhibitors, 2019
• Filed and Phase III Products, 2019
• Phase II Products, 2019
• Phase I and IND Filed Products, 2019
• Discovery and Pre-Clinical Stage Products, 2019
• Fibroblast Activation Protein (FAP or Seprase) Inhibitors Assessment by Monotherapy Products
• Fibroblast Activation Protein (FAP or Seprase) Inhibitors Assessment by Combination Products
• Fibroblast Activation Protein (FAP or Seprase) Inhibitors Assessment by Route of Administration
• Fibroblast Activation Protein (FAP or Seprase) Inhibitors Assessment by Stage and Route of Administration
• Fibroblast Activation Protein (FAP or Seprase) Inhibitors Assessment by Molecule Type
• Fibroblast Activation Protein (FAP or Seprase) Inhibitors Assessment by Stage and Molecule Type


【レポートのキーワード】

繊維芽細胞活性化タンパク質阻害剤、医薬品、製薬、研究開発、パイプライン、治療、治験

★調査レポート[繊維芽細胞活性化タンパク質阻害剤のパイプライン・インサイト2019] (コード:DIMR2016283)販売に関する免責事項を必ずご確認ください。
★調査レポート[繊維芽細胞活性化タンパク質阻害剤のパイプライン・インサイト2019]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆